iCAD, Inc. (ICAD) Announces Positive Three-Year Data Using the Xoft System to Treat Skin Cancer Presented at ASTRO
9/25/2013 6:35:07 AM
Booth Number 2449 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that positive data using the Company’s Xoft® Axxent® Electronic Brachytherapy System® to treat non-melanoma skin cancer (NMSC) were presented today at the American Society of Radiation Oncology’s (ASTRO) 55th Annual Meeting being held from September 22-25, 2013 in Atlanta.
Help employers find you! Check out all the jobs and post your resume.
comments powered by